Navigation Links
Formedix Releases Transform for OpenClinica to Drive Efficiencies in Clinical Trials
Date:11/19/2013

Burlington, MA (PRWEB) November 19, 2013

Formedix, leading provider of clinical trial automation software and consultancy services, is delighted to announce the new product release, as a result of their partnership with OpenClinica, LLC, producers of the world’s most widely used open source electronic data capture software. The collaboration brings an integration between Formedix Origin universal clinical trial design tools and OpenClinica’s uniquely flexible open source system for Electronic Data Capture (EDC) and Clinical Data Management to the market.

The product, named Formedix Transform for OpenClinica, is now available and joins the leading range of EDC integrations offered by Formedix. Transform for OpenClinica integrates with Formedix Universal Design Tool, Origin, to merge study specification and EDC build into one process which significantly reduces OpenClinica study build times-in some cases by more than 65%. Other capabilities include study build automation and drag-and-drop reuse, enhanced by leveraging portable, vendor neutral CDISC designs.

CROs and sponsors now have even greater choice when selecting an EDC system with the introduction of Transform for OpenClinica and its diverse capabilities. Companies no longer need to struggle to meet sponsor requests or train in multiple EDC systems because, with Formedix, training only needs to be given for one study design tool.

Mark Wheeldon, CEO of Formedix, was invited to present at OC13, the 2013 OpenClinica Global Conference, earlier this year, to discuss using CDISC standards to drive efficiencies in study set-up and build with OpenClinica. He also spoke in detail about how Formedix is working with partners, such as OpenClinica, to develop cutting-edge solutions to help achieve further reductions in study build times.

Mark said, “Formedix Transform enables users to design in one environment and interface with multiple systems, broadening the scope of CROs and EDC vendors. By providing a vendor neutral solution, our customers can choose one, work with all. Transform for OpenClinica allows us to continue our ongoing mission of delivering more choice for study build, as well as reducing the need for training in multiple systems.”

He added, “We are the only independent provider of multi-vendor solutions for clinical trial automation and we continue to build our network of technology partnerships to enhance this proposition. We are delighted to add to our wide portfolio of Transform tools and partner with OpenClinica, to offer even more choice to our customers.”

Today, Formedix also has Transform integrations with Medidata Rave, Nextrial’s Prism, Perceptive Informatics’ DataLabs and OmniComm System’s TrialMaster as well as the ability to publish paper CRFs and Define.pdf.

Visit the Formedix Resources page to download a free trial of Transform for OpenClinica, or to express an interest in partnering with the company to build an EDC integration, contact Formedix.

About Formedix

Formedix clinical trial automation software and services enable you to remove manual, expensive, inefficient and labor intensive tasks from study set-up, EDC build, validation and submission publication processes.

In fact, across every facet of your end-to-end clinical trial, the time and cost savings they deliver speak for themselves and continue to do so time and time again...

Formedix saves 68% in set-up time and 55% in EDC build time. With 70% reuse of your content, resources are cut by 23%. It’s all in the numbers.

Your Clinical Trials Automated. Everywhere.

About OpenClinica

OpenClinica, LLC is the global leader in open source EDC | CDMS software with thousands of implementations at contract research organizations, biopharmaceutical companies, academic, and government organizations. The powerful tools and superior quality system increase the speed of data collection and ensure data integrity in clinical trials. OpenClinica supports ICH, GCP, 21 CFR Part 11, HIPAA, and other regulatory guidelines, and is designed as a standards-based, extensible, and modular platform.

For more information visit https://www.openclinica.com.

Read the full story at http://www.prweb.com/releases/2013/11/prweb11349062.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. "Collaborate to Innovate" with Formedix at DIA Annual Meeting 2012
2. Formedix Partners with Perceptive Informatics for Forthcoming Webcast, “Four Secrets to Using CDISC Standards to Enable Clinical Trial Efficiencies”
3. Formedix to Host Webinar: Discover Define-XML - Practical Uses Today and a Technical Deep Dive on March 14, 2013
4. Formedix and OmniComm Partner to Offer CRO and Sponsors Multi-Vendor EDC Capabilities
5. Formedix to Host Executive Breakfast prior to Bay Area CDISC Network Meeting, May 23, 2013
6. Take a Standards Health Check with Formedix at DIA 49th Annual Meeting
7. Formedix CEO Invited to Speak at OpenClinica Global Conference in Boston
8. Formedix Partners With OpenClinica to Deliver Automated End-to-End Clinical Trial Builds
9. HealthCare Institute of New Jersey Releases 2011 Biopharmaceutical and Medical Technology Economic Impact Data
10. HCCS Releases ICD-10 Countdown Clock With Integrated CMS Twitter Tweets
11. eCareSoft Releases eCS Cirrus™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... May 05, 2016 , ... American Process, Inc. ... patents, U.S. Patent Nos. 9,322,133 and 9,322,134, to API and its affiliated companies ... well as hydrophobic nanocellulose compositions. In addition to these patents and U.S. ...
(Date:5/4/2016)... ... May 05, 2016 , ... ... support the National Stroke Association during National Stroke Awareness Month in May. ... Twitter pages throughout the month. CereScan will donate $1 up to a ...
(Date:5/4/2016)... , May 4, 2016  Bayer today announced ... compound Stivarga ® (regorafenib) tablets for the ... has met its primary endpoint of a statistically ... RESORCE, evaluated the efficacy and safety of regorafenib ... after treatment with sorafenib. The safety and tolerability ...
(Date:5/4/2016)... ... 04, 2016 , ... PBI-Gordon Corporation is pleased to announce Doug Obermann has ... his career at PBI-Gordon in February 1988, after finishing his masters in agronomy from ... from customer service to national product manager, to helping develop, name and launch many ...
Breaking Biology Technology:
(Date:3/10/2016)... March 10, 2016 --> ... research report "Identity and Access Management Market by Component ... and Governance), by Organization Size, by Deployment, by Vertical, ... by MarketsandMarkets, The market is estimated to grow from ... by 2020, at a Compound Annual Growth Rate (CAGR) ...
(Date:3/8/2016)... 2016   Valencell , the leading innovator ... has secured $11M in Series D financing. The ... venture fund being launched by UAE-based financial services ... investors TDF Ventures and WSJ Joshua Fund. Valencell ... triple-digit growth and accelerate its pioneering innovation in ...
(Date:3/2/2016)... , March 2, 2016 ... addition of the "Global Biometrics as ... their offering. --> http://www.researchandmarkets.com/research/cmt3hk/global_biometrics ... "Global Biometrics as a Service Market ... --> Research and Markets ( ...
Breaking Biology News(10 mins):